[Featured Stock] HanmiScience Surges Over 10% Amid 'Management Rights Dispute' Possibility

The stock price of Hanmi Science, the holding company of Hanmi Pharmaceutical Group that announced a merger plan with OCI Group, is showing double-digit gains.

As of 11:52 a.m. on the day, Hanmi Science's stock price is trading at 42,400 KRW, up 4,000 KRW (10.42%) compared to the previous trading day.

Earlier, on the 12th, Hanmi Science announced that it would conduct a third-party allotment paid-in capital increase worth 240 billion KRW targeting OCI Holdings. OCI Holdings, the holding company of OCI Group, will acquire a total of 27% of Hanmi Science's shares, the holding company of Hanmi Pharmaceutical Group, by investing 770.3 billion KRW, including 18.6% through existing shares and in-kind contributions and 8.4% through new share issuance. Additionally, major shareholders of Hanmi Science, including the late Chairman Lim Sung-ki's eldest daughter, Lim Juhyun, Head of Strategic Planning, will acquire 10.4% of OCI's shares.

Currently, Song Young-sook, the widow of the late Chairman Lim Sung-ki who led the overall management of Hanmi Pharmaceutical Group and spearheaded this integration, and Lim Juhyun have shareholding ratios of 11.66% and 10.2%, respectively. However, after the merger plan announcement, the eldest son, Lim Jong-yoon, President of Hanmi Pharmaceutical, has opposed it, increasing the possibility of a management rights dispute. Lim holds 9.91% of the shares, and the second son, Lim Jong-hoon, who is known to share the same views as Lim, holds 10.56% of the shares.